$PYPD

PolyPid Ltd. (Nasdaq: PYPD) said the FDA accepted its D-PLEX100 NDA for priority review for preventing surgical site infections in abdominal colorectal surgery, with a PDUFA goal date of Nov. 28, 2026. PolyPid entered an exclusive U.S. and Canada commercialization partnership with Azurity, receiving $30 million upfront and near-term milestones, plus tiered mid-teen to mid-twenties royalties. Q2 2026 net loss was $7.8M.

PolyPid (Nasdaq: PYPD) said the FDA accepted its NDA for D-PLEX100 to prevent surgical site infections in abdominal colorectal surgery and granted Priority Review. The PDUFA target action date is Nov. 28, 2026. FDA found no filing review issues. Acceptance triggers a $15 million milestone from Azurity, completing $30 million in upfront and near-term milestones.

PolyPid Ltd. (PYPD) said it signed an exclusive commercialization deal with Azurity Pharmaceuticals for D-PLEX100 to prevent abdominal surgical site infections in the U.S. and Canada. PolyPid gets $15M upfront, $15M on FDA NDA acceptance, and up to $300M in milestones. Deal follows Phase 3 SHIELD II results; U.S. launch targeted Q1 2027. Analysts at Roth and H.C. Wainwright set Buy ratings and $9 and $13 targets.

PETACH TIKVA, Israel, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- PolyPid Ltd. ( NASDAQ:PYPD ) ( "PolyPid" or the "Company" ) , a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present the topline results from the Company's successful ...

The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences ...

PETACH TIKVA, Israel, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- PolyPid Ltd. PYPD ( "PolyPid" or the "Company" ) , a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor Conference on ...

PETACH TIKVA, Israel, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- PolyPid Ltd. ( Nasdaq: PYPD ) ( "PolyPid" or the "Company" ) , a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Craig-Hallum cut PolyPid Ltd. PYPD price target from $15 to $13.

Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI ...

Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding ...